ABSTRACT-The present study was designed to demonstrate the existence in canine aorta of a1-adreno ceptor subtypes, alffigh and a1Low, that have different binding affinities for 3H-prazosin and to assess the bind ing affinity of several drugs for each subtype by a displacement experiment. A radioligand binding assay with 3H-prazosin revealed the presence of two a1-adrenoceptor subtypes in the canine aorta. One of them which has a high affinity for prazosin was designated as alffigh (Kd: 12.40 pM, Bmax: 21.88 fmol/mg protein), and the other type was designated as a1LoW (Kd: 506.03 pM, Bmax: 88.22 fmol/mg protein). The pK1 values of several drugs for each subtype were determined, and all drugs used in the present study, except for benoxa thian and chlorethylclonidine, showed significant differences between the pK; values for alffigh and those for a1LoW. Although it is difficult to characterize each alffigh and a1Low into a1A or a1B by only the displacement potency, one structural characteristic to distinguish between alHigh and a1LoW could be evaluated.
The relationship between vascular smooth muscle con traction and the stimulation of a1-adrenoceptors has been well established (1) . In the canine aorta, the existence of an a1-adrenoceptor was demonstrated by both radio ligand binding assay and pharmacological methods (2) . Recently, an increasing number of a1-adrenoceptor sub classifications have been proposed through evidence ob tained in pharmacological and/or radioligand binding studies (3 10) . Our previous reports also described that 3H -prazosin discriminated the a1-adrenoceptor subtypes with different affinities in bovine prostate (11) and rat brain, spleen (12) and heart (13); these subtypes were termed a1Hlgh and a1Low, respectively.
The present study was performed to demonstrate the existence of these a1-adrenoceptor subtypes (aiHigh and a1LoW) in the canine aorta and to assess the displacement potency (pK, value) of several drugs for each subtype by means of radioligand binding assays.
MATERIALS AND METHODS

Preparation
of a crude membrane-enriched specimen from the canine aorta This was done by essentially the same method as described previously (2) . In brief, the aorta was removed, frozen in liquid nitrogen and stored at 801C until used. The specimen of frozen aorta in the liquid nitrogen was crushed into a fine powder by a mortar and a pestle. After being crushed, this tissue was weighed and suspended in 10 vol. of 10 mM Tris-HCl buffer containing 250 mM sucrose, pH 7.6. The suspension was homogenized with a Politron homogenizer about 5 times for 10 sec at setting 8 and then filtered through 1 layer of gauze. The filtrate was centrifuged for 10 min at 1000 x g, and the supernatant obtained was again centrifuged for 30 min at 40000 X g. The resulting pellet was rinsed once with the incubation buffer (120 mM Tris-HCI, pH 7.4) and homogenized with a glass homogenizer in 1 vol. of the same buffer. The mem brane-enriched fraction was then immediately frozen in liquid nitrogen and stored at 80'C until used. Protein concentration was determined by the method of Lowry et al. (14) , with bovine serum albumin as the standard.
Binding assay
The a1-adrenoceptor subtypes in the canine aorta were examined with 3H-prazosin as the radioligand. All bind ing assays in the present study were carried out in dupli cate, and the results were reported as the means obtained from 3 6 experiments. In the saturation experiment, the concentration of 3H-prazosin ranged from 0.01 3.5 nM; and in the displacement experiment for aiHigh and a1LOW, it was 0.01 and 0.3 nM, respectively. The binding assay of alLow alone was carried out with the membrane suspen sion in the presence of 1 nM bunazosin as well as by a previously described method (11) . The prepared medium that contained 3H-prazosin, some a,-antagonist and mem brane (0.15 mg of protein) in 0.5 ml of 60 mM Tris-HC1 buffer, pH 7.4, was incubated at 231C for 30 min and then terminated by rapid filtration under vacuum through glass fiber filters (Whatman GF/C, Whatman Inter national Ltd., Maidstone, UK) using an Automatic Cell Harvester Labomash (LM-101, Labo Science, Tokyo). The resulting filters were added to 1 ml of toluene-triton based scintillation fluid, and the radioactivity was count ed by a liquid scintillation counter (Packard 2200 Tri-Cab Scintillation Analyzer, Packard Japan K.K., Tokyo). The specific binding of 3H-prazosin was defined as the differ ence between the total binding and the nonspecific bind ing obtained in the presence of 10 pM phentolamine. The values of the inhibition constants (K;) were calculated by a previously described method (15) (Chugai, Tokyo), terazosin (Mitsubishi Kasei, Tokyo) and nifedipine (Sumitomo Chemical, Osaka) were kindly donated by each company. All com pounds used in the present study, except for nifedipine, were dissolved in and diluted with distilled water. Nifedi pine was dissolved in ethanol and diluted with distilled water to the appropriate concentrations.
All prepared compounds were stored at 41C. This binding assay was used in the displacement experi ment shown in Fig. 2 and applied thereafter to the deter mination of alLow. Table 1 summarizes the values of the dissociation con stants (Kd) and the maximum numbers of alHigh and alLow binding sites (Borax) for 3H-prazosin in the canine aorta. Data in the upper and lower rows were obtained from the Scatchard analysis of saturation experiments carried out in the absence (Fig. 1, a and b ) and in the presence ( To further characterize the a1-adrenoceptor subtypes in the canine aorta using the displacement potencies (pKi values) of several drugs, the displacement experiment was performed for each binding site of 3H-prazosin. Figure 2 shows a typical displacement curve of bunazosin using different concentrations of 3H-prazosin. One curve is shal low with a higher concentration (0.3 nM) of 3H-prazosin. This suggests that bunazosin displaced two different bind ing sites of 3H-prazosin. The other curve resulting from the lower concentration (0.01 nM) of 3H-prazosin appears to approximate a monophasic pattern. However, this curve shows that a low concentration of bunazosin dis places 3H-prazosin bound to alHigh (85%) and a high con centration of bunazosin displaces 3H-prazosin bound to alLow (15%). This 3H-prazosin binding ratio of alHigh/ alLow is variable depending upon the concentration of 3H -prazosin used (ex . 85 : 15 using 0.01 nM 3H-prazosin) and can be calculated according to the method of Tsuchi hashi et al. (15) (16) (17) . Consequently, it was possible to ob tain the pKi values of several drugs from the displacement experiments using 0.01 nM 3H-prazosin (Fig. 2) . Further more, this curve suggests that a bunazosin concentration lower than 1 nM was bound only to aiHigh, because the dis placement potency for each subtype of bunazosin is con stant and independent of each other. Thus, this concentra tion (1 nM) was applied to the assay of alLow in order to mask only alHigh. Figure 3 shows a typical displacement curves of prazosin. As already mentioned, the experiment using 0.01 nM 3H-prazosin gave us the displacement potency for aluigh, whereas the experiment using 0.3 nM 3H -prazosin in the presence of 1 nM bunazosin gave us that for alLow. There was no difference in the Ki value ob tained from the displacement curve or the Kd value from the Scatchard analysis. Table 2 summarizes the pKi values of several drugs for a1-adrenoceptor subtypes in the canine aorta. For most drugs, a significant difference of the potency for each sub type was found; however, no difference was shown for benoxathian or chlorethylclonidine. Table 1 .
Binding characteristics of 3H-prazosin for a,-adrenoceptor subtypes in canine aortas Fig. 3 . Displacement curves of prazosin using 0.3 nM 3H-prazosin in the presence (0) and 0.01 nM 3H-prazosin in the absence (0) of 1 nM bunazosin. B1 or BO is the concentration of 3H-prazosin bound in the presence or absence of prazosin. 
DISCUSSION
The binding assay using 3H-prazosin proved the exist ence of a,-adrenoceptor subtypes (a,High and a,LoW) with different affinities for 3H-prazosin in canine aorta. Not all the pKi values for each subtype in canine aorta (Table 2) were in agreement with those in rat brain, spleen, heart and bovine prostate in our previous reports (11 13) . This different binding affinity of some drugs suggests that aiHigh and alLow in the canine aorta are not the same as those in the other tissues.
Several investigators (3 10) have also reported that a, adrenoceptor subtypes could be distinguished by the bind ing affinity of an antagonist or pharmacological specific ity. Among them, Morrow and Creese (7) reported that the a,-adrenoceptor could be subclassified into a,A and a,B by the radioligand binding assay method using 3H prazosin and 3H-WB4101. Namely, a,-adrenoceptor sub types were characterized as a,A when the ratio of the potency (Ki or Kd) of phentolamine versus prazosin was about 4 and the aiB was about 80. In the present study, this ratio was 309.0 at aiHigh and 467.7 at a,LoW. These values suggested that both a,High and alLow in the canine aorta may be characterized as a,B. Furthermore, Han et al. showed that the involvement of extracellular Ca" in contraction is different between the a,A and a,B subtypes (4), and they described the characteristics of each subtype as follows: The a,A has a high affinity for WB-4101, phen tolamine, 5-methylurapidil and (+ )nigludipine and is not sensitive to chlorethylclonidine (CEC). The a,B-subtype has a 20 to 1500-fold lower affinity for the antagonists mentioned and is sensitive to CEC (5). The binding affin ity of WB-4101 and phentolamine to a,High was 65 and 129-fold higher than that to a,LoW, respectively. On the other hand, the binding affinity of CEC to aiHigh was very low and showed no significant difference from that to a,Low. These observations suggested that data on only the binding affinity of WB-4101, phentolamine and CEC could not clearly characterize each alHigh and alLow into a,A or a,B. Further investigation for the optimum ex perimental method or conditions (e.g., the incubation time, temperature or CEC-treated condition) may solve this problem of characterizing each aiHigh and alLow into alA or a,B. Thus, the a,-adrenoceptor subtypes in the present study should still be called a,High and alLoW. One structural characteristic that may distinguish between a, High and a,LoW was suggested by the comparison of the chemical structures of benoxathian and WB-4101 or CEC and phenoxybenzamine (PBZ). As shown in Table 2 , benoxathian and CEC could not distinguish be tween alHigh and a,LoW. On the other hand, WB-4101 and PBZ, although having partially the same structures as benoxathian and CEC, respectively, could be distin guished by each subtype. First, WB-4101 contains an oxy gen atom in the benzo-1,4-dioxanmethyl group that is replaced with a sulfur atom in benoxathian. This oxygen atom in WB-4101 may result in the higher affinity for aiHigh than that for a,LoW. Secondly, both PBZ and CEC contain the f3-chlorethylbenzylamine skeleton. It is well known that this skeleton changes to the benzylaziridium ion and irreversibly binds to the a,-adrenoceptor.
Thus, the recognition of each a,-adrenoceptor subtype may be due to the side-chain binding to the nitrogen atom.
In conclusion, using the radioligand binding assay method, we have proved the existence of a,-adrenoceptor subtypes (a, High and a,Low) in canine aorta and demonstrat ed the binding characteristics of each site. There are some difficulties in correlating the subclassification in the present study (a,High and a,LOW) and that in the previous reports (a,A and a,B). To clarify the a,-adrenoceptor sub classification, not only the binding affinity of drugs for each subtype, but also their roles in contraction should be used as criteria.
